However, we note that less than 20% of patients with mOGC will have overexpression of HER2. Increasing understanding of molecular pathways and the dependence of each tumour on angiogenesis may identify subgroups of patients with mOGC who may benefit most from AAs. The gene discussed is ERBB2; the disease is neoplasm.